Progress in endocrine therapy for breast carcinoma

Cancer

Volumn 83, Issue 1, 1998, Pages 1-6

  Hortobagyi, Gabriel N ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; ANTIESTROGEN; ANTIGESTAGEN; AROMATASE INHIBITOR; ESTROGEN; ESTROGEN RECEPTOR; GESTAGEN; GONADORELIN DERIVATIVE; LETROZOLE; MEDROXYPROGESTERONE ACETATE; MEGESTROL ACETATE; NAFOXIDINE; PROGESTERONE RECEPTOR; PROTEIN P53; TAMOXIFEN;

ADRENALECTOMY; BREAST CARCINOMA; CANCER HORMONE THERAPY; CLINICAL TRIAL; DRUG MECHANISM; HUMAN; HYPOPHYSECTOMY; ONCOGENE NEU; OVARIECTOMY; PRIORITY JOURNAL; REVIEW;

AROMATASE INHIBITORS; BREAST NEOPLASMS; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; PROGESTINS;

EID: 0032125563     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19980701)83:1<1::AID-CNCR1>3.0.CO;2-X     Document Type: Review

References (64)

1. Hortobagyi GN. Endocrine treatment of breast cancer. In: Becker KL, editor. Principles and practice of endocrinology and metabolism. Philadelphia: J.B. Lippincott Company, 1995:1868-75.
2. Horwitz KB, Costlow ME, McGuire WL. MCF-7: a human breast cancer cell line with estrogen, androgen, progesterone, and glucocorticoid receptors. Steroids 1975;26:785-95.
3. Levenson AS, Jordan VC. MCF-7: the first hormone-responsive breast cancer cell line. Cancer Res 1997;57:3071-8.
4. McGuire WL, Carbone PP, Sears ME, Escher GC. Estrogen receptors in human breast cancer: an overview. In: McGuire WL, Carbone PP, Vollmer EP, editors. Estrogen receptors in human breast cancer. New York: Raven, 1975:1-7.
5. Horwitz KB, McGuire WL. Estrogen and progesterone: their relationship in hormone-dependent breast cancer. In: McGuire WL, Raynaud JP, Baulieu EE, editors. Progesterone receptors in normal and neoplastic tissues. New York: Raven Press, 1977:103-24.
6. Nolvadex Adjuvant Trial Organization. Controlled trial of tamoxifen as adjuvant agent in management of early breast cancer -Interim analysis at four years. Lancet 1983; i:257-61.
7. The Ludwig Breast Cancer Study Group. Randomised trial of chemo-endocrine therapy, endocrine therapy, and mastectomy alone in postmenopausal patients with operable breast cancer and axillary node metastasis. Lancet 1984;i: 1256-60.
8. Anonymous. Adjuvant tamoxifen in the management of operable breast cancer: the Scottish Trial. Report from the Breast Cancer Trials Committee, Scottish Cancer Trials Office (MRC), Edinburgh. Lancet 1987;2:171-5.
9. Anonymous. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group [see comments]. Lancet 1992;339:71-85.
10. Anonymous. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group [review] [see comments]. Lancet 1992;339:1-15.
11. Knight WA, Livingston RB, Gregory EJ, McGuire WL. Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer. Cancer Res 1977;37: 4669-71.
12. Howell A, Barnes DM, Harland RN, Redford J, Bramwell VH, Wilkinson MJ, et al. Steroid-hormone receptors and survival after first relapse in breast cancer. Lancet 1984;1:588-91.
13. McGuire WL. Hormone receptors: their role in predicting prognosis and response to endocrine therapy. Semin Oncol 1978;5:428-33.
14. Samaan NA, Buzdar AU, Aldinger KA, Schultz PN, Yang KP, Romsdahl MM, et al. Estrogen receptor: a prognostic factor in breast cancer. Cancer 1981;47:554-60.
15. Mason BH, Holdaway IM, Mullins PR, Yee LH, Kay RG. Progesterone and estrogen receptors as prognostic variables in breast cancer. Cancer Res 1983;43:2985-90.
16. Clark GM, Osborne CK, McGuire WL. Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer. J Clin Oncol 1984;2: 1102-9.
17. Clark GM, Sledge GW Jr., Osborne CK, McGuire WL. Survival from first recurrence: relative importance of prognostic factors in 1,015 breast cancer patients. J Clin Oncol 1987;5:55-61.
18. Shek LL, Godolphin W. Survival with breast cancer: the importance of estrogen receptor quantity. Eur J Cancer Clin Oncol 1989;25:243-50.
19. Raemaekers JM, Beex LV, Koenders AJ, Pieters GF, Smals AG, Benraad TJ, et al. Disease-free interval and estrogen receptor activity in tumor tissue of patients with primary breast cancer: analysis after long-term follow-up. Breast Cancer Res Treat 1985;6:123-30.
20. Andry G, Suciu S, Pratola D, Sylvester R, Leclercq G, da Costa PM, et al. Relation between estrogen receptor concentration and clinical and histological factors: their relative prognostic importance after radical mastectomy for primary breast cancer. Eur J Cancer Clin Oncol 1989;25:319-29.
21. Crowe JP Jr., Gordon NH, Hubay CA, Shenk RR, Zollinger RM, et al. Estrogen receptor determination and long term survival of patients with carcinoma of the breast. Surg Gynecol Obstet 1991;173:273-8.
22. Legha SS, Carter SK. Antiestrogens in the treatment of breast cancer. Cancer Treat Rev 1976;3:205-16.
23. Legha SS, Slavik M, Carter SK. Nafoxidine - an antiestrogen for the treatment of breast cancer. Cancer 1976;38:1535-41.
24. Jaiyesimi IA, Buzdar AU, Decker DA, Hortobagyi GN. Use of tamoxifen for breast cancer: twenty-eight years later [review] [see comments]. J Clin Oncol 1995;13:513-29.
25. Matelski H, Greene R, Huberman M, Lokich J, Zipoli T. Randomized trial of estrogen vs. tamoxifen therapy for advanced breast cancer. Am J Clin Oncol 1985;8:128-33.
26. Lipton A, Harvey HA, Santen RJ, Boucher A, White D, Bernath A, et al. A randomized trial of aminoglutethimide versus tamoxifen in metastatic breast cancer. Cancer 1982;50: 2265-8.
27. Ettinger DS, Allegra J, Bertino JR, Bonomi P, Browder H, Byrne P, et al. Megestrol acetate v tamoxifen in advanced breast cancer: correlation of hormone receptors and response. Semin Oncol 1986;13:9-14.
28. Muss HB, Wells HB, Paschold EH, Black WR, Cooper MR, Capizzi RL, et al. Megestrol acetate versus tamoxifen in advanced breast cancer: 5-year analysis - a Phase III trial of the Piedmont Oncology Association. J Clin Oncol 1988;6: 1098-106.
29. Buchanan RB, Blamey RW, Durrant KR, Howell A, Paterson AG, Preece PE, et al. A randomized comparison of tamoxifen with surgical oophorectomy in premenopausal patients with advanced breast cancer. J Clin Oncol 1986;4:1326-30.
30. Ingle JN, Krook JE, Green SJ, Kubista TP, Everson LK, Ahmann DL, et al. Randomized trial of bilateral oophorectomy versus tamoxifen in premenopausal women with metastatic breast cancer. J Clin Oncol 1986;4:178-85.
31. Lopez M, Di Lauro L, Lazzaro B, Papaldo P. Hormonal treatment of disseminated male breast cancer. Oncology (Huntingt) 1985;42:345-9.
32. Hortobagyi GN, DiStefano A, Legha SS, Buzdar AU, Blumenschein GR. Hormonal therapy with tamoxifen in male breast cancer. Cancer Treat Rep 1979;63:539-41.
33. Kantarjian H, Yap HY, Hortobagyi G, Buzdar A, Blumenschein G. Hormonal therapy for metastatic male breast cancer. Arch Intern Med 1983;143:237-40.
34. Fisher B, Redmond C, Brown A, Wolmark N, Wittliff J, Fisher ER, et al. Treatment of primary breast cancer with chemotherapy and tamoxifen. N Engl J Med 1981;305:1-6.
35. Anonymous. Randomised trial of chemo-endocrine therapy, endocrine therapy, and mastectomy alone in postmenopausal patients with operable breast cancer and axillary node metastasis. Ludwig Breast Cancer Study Group. Lancet 1984;1:1256-60.
36. Wallgren A, Baral E, Glas U, Karnstrom L, Nordenskiord B, Theve NO, et al. Adjuvant tamoxifen treatment in postmenopausal patients with operable breast cancer. J Steroid Biochem Mol Biol 1985;23:1161-2.
37. Love RR. Tamoxifen in axillary node-negative breast cancer: multisystem benefits and risks [review]. Cancer Invest 1992; 10:587-93.
38. Goldhirsch A, Gelber RD. Endocrine therapies of breast cancer [review]. Semin Oncol 1996;23:494-505.
39. Muss HB, Cruz JM. High-dose progestin therapy for metastatic breast cancer [review]. Ann Oncol 1992;3(Suppl 3): 15-20.
40. Canetta R, Florentine S, Hunter H, Lenaz L. Megestrol acetate. Cancer Treat Rev 1983;10:141-57.
41. Muss HB, Case LD, Atkins JN, Bearden J, 3rd, Cooper MR, Cruz JM, et al. Tamoxifen versus high-dose oral medroxyprogesterone acetate as initial endocrine therapy for patients with metastatic breast cancer: a Piedmont Oncology Association study [see comments]. J Clin Oncol 1994;12: 1630-8.
42. Cavalli F, Goldhirsch A, Jungi F, Martz G, Mermillod B, Alberto P. Randomized trial of low-versus high-dose medroxyprogesterone acetate in the induction treatment of postmenopausal patients with advanced breast cancer. J Clin Oncol 1984;2:414-9.
43. Anonymous. New aromatase inhibitors for breast cancer [review]. Drug Ther Bull 1997;35:55-6.
44. Brodie AM, Njar VC. Aromatase inhibitors and breast cancer [review]. Semin Oncol 1996;23:10-20.
45. Buzdar AU, Plourde PV, Hortobagyi GN. Aromatase inhibitors in metastatic breast cancer. Semin Oncol 1996;23:28-32.
46. Buzdar AU, Jones SE, Vogel CL, Wolter J, Plourde P, Webster A. A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma. Arimidex Study Group. Cancer 1997;79:730-9.
47. Nemoto T, Patel J, Rosner D, Dao TL. Tamoxifen (Nolvadex) versus adrenalectomy in metastatic breast cancer. Cancer 1984;53:1333-5.
48. Wells SA Jr., Santen RJ. Ablative procedures in patients with metastatic breast carcinoma. Cancer 1984;53:762-5.
49. Klijn JGM, Seynaeve C, Beex L, Mauriac L, van Zijl J, Veyret C, et al. Combined treatment With buserelin (LHRH-A) and tamoxifen vs single treatment with each drug alone in premenopausal metastatic breast cancer: preliminary results of EORTC study 10881 [abstract 132]. Proc Am Soc Clin Oncol 1996;15:117.
50. Taylor CW, Green S, Dalton WS, Martino S, Ingle JN, Robert NJ, et al. A multi-center randomized trial of zoladex versus surgical ovariectomy in pre-menopausal patients with receptor positive metastatic breast cancer [abstract 19]. Breast Cancer Res Treat 1996;37:37.
51. Boccardo F, Rubagotti A, Perrotta A, Amoroso D, Balestrero M, de Matteis A, et al. Ovarian ablation versus goserelin with or without tamoxifen in pre-perimenopausal patients with advanced breast cancer: results of a multicentric Italian study. Ann Oncol 1994;5:337-42.
52. Jordan VC. Estrogen receptor-mediated direct and indirect antitumor effects of tamoxifen. J Natl Cancer Inst 1990;82: 1662-3.
53. Love RR, Newcomb PA, Wiebe DA, Surawicz TA, Jordan VC, Carbone PP, et al. Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with node-negative breast cancer [see comments]. J Natl Cancer Inst 1990;82:1327-32.
54. Jordan VC. Molecular mechanisms of antiestrogen action in breast cancer [review]. Breast Cancer Res Treat 1994;31:41-52.
55. Assikis VJ, Jordan VC. Tamoxifen and endometrial cancer: from experiment to patient [review]. Recent Results Cancer Res 1996;140:61-71.
56. Catherine WH, Jordan VC. A point mutation in the estrogen receptor from a tamoxifen-stimulated human breast cancer can explain the change of tamoxifen pharmacology from an antiestrogen to an estrogen [abstract]. Breast Cancer Res Treat 1994;32:32.
57. Draper MW, Flowers DE, Huster WJ, Neild JA, Harper KD, Arnaud C. A controlled trial of raloxifene (LY139481) HCl: impact on bone turnover and serum lipid profile in healthy postmenopausal women. J Bone Miner Res 1996; 11:835-42.
58. Paech K, Webb P, Kuiper GG, Nilsson S, Gustafsson I, Kushner PJ, et al. Differential ligand activation of estrogen receptors ERalpha and ERbeta at API sites. Science 1997;277:1508-10.
59. Howell A, Downey S, Anderson E. New endocrine therapies for breast cancer [review]. Eur J Cancer 1996;32A:576-88.
60. Rutqvist LE. Randomized adjuvant breast cancer trials in Sweden. Cancer 1994;74(Suppl):1156-9.
61. Sluyser M. Nuclear hormone receptor variants: their role in malignancy and progression to hormone resistance in cancer. Acta Endocrinol 1991;126:48-53.
62. Silvestrini R, Benini E, Veneroni S, Daidone MG, Tomasic G, Squicciarini P, et al. p53 and bcl-2 expression correlates with clinical outcome in a series of node-positive breast cancer patients. J Clin Oncol 1996;14:1604-10.
63. Yamauchi H, O'Neill A, Gelman R, Carney W, Hosch S, Kufe DW, et al. Elevated circulating HER-2/neu-related protein (NRP) is associated with low response rate (RR) to first-line hormone therapy (HT) in patients with estrogen and/or progesterone receptor positive (ER, PR Pos) advanced breast cancer (AdBrCA) [meeting abstract]. Proc Annu Meet Am Soc Clin Oncol 1996;15:A116.
64. Taylor SG III, Slaughter DP, Smejkal W, Fowler EF, Preston FW. The effect of sex hormones on advanced carcinoma of the breast. Cancer 1948;1:604-17.